Apollo Therapeutics has completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the company during 2023 to $260 million. Apollo is a UK-based biopharmaceutical company advancing a pipeline of therapeutic programmes in oncology, major inflammatory disorders and rare diseases. The company […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!